雷贝拉唑三联疗法治疗消化性溃疡病的效果

Effect of Rabeprazole-based triple therapy in the treatment of peptic ulcer disease

目的探讨雷贝拉唑三联疗法治疗消化性溃疡病的效果。方法选取天津市第四中心医院2017年1月~2019年1月收治的80例消化性溃疡病患者作为研究对象,按照随机数字表法分为奥美拉唑组(40例)与雷贝拉唑组(40例)。奥美拉唑组采用奥美拉唑三联疗法,雷贝拉唑组采用雷贝拉唑三联疗法。分析两种方法的疗效、安全性。结果雷贝拉唑组的治疗总有效率高于奥美拉唑组,差异有统计学意义(P<0.05);雷贝拉唑组的临床症状积分、血清白细胞介素-6、C反应蛋白、肿瘤坏死因子-α水平低于奥美拉唑组,差异有统计学意义(P<0.05)。两组治疗后的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论在消化性溃疡病治疗中,雷贝拉唑三联疗法的治疗效果更佳,可改善临床症状,降低血清白细胞介素-6、C反应蛋白、肿瘤坏死因子-α水平,值得临床推广。

Objective To investigate the effect of Rabeprazole-based triple therapy in the treatment of peptic ulcer disease.Methods A total of 80 patients with peptic ulcer disease admitted to Tianjin Fourth Central Hospital from January 2017 to January 2019 were selected as research objects,and they were divided into the Omeprazole group(40 cases)and the Rabeprazole group(40 cases)according to the random number table method.The Omeprazole group was treated with Omeprazole triple therapy,the Rabeprazole group was treated with Rabeprazole triple therapy.The efficacy and safety of the two methods were analyzed.Results The total effective rate of the Rabeprazole group was higher than that of the Omeprazole group,with statistically significant difference(P<0.05).While the clinical symptom score,the levels of serum interleukin-6,C-reactive protein,and tumor necrosis factor-α levels of the Rabeprazole group were lower than those of the Omeprazole group,with statistically significant difference(P<0.05).There was no significant difference in the total incidence of adverse reactions after treatment between the two groups(P>0.05).Conclusion Rabeprazole-based triple therapy in the treatment of peptic ulcer disease has better therapeutic effect,can improve clinical symptom,reduce serum interleukin-6,C-reactive protein,and tumor necrosis factor-αlevels.It is worthy of clinical promotion.